Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$33.38+0.40 (+1.21%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%
Castle Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Castle Biosciences's revenue for the twelve months ending Sep 30, 2026 was $377.13M, up 9.8% year over year. For fiscal 2025 it was $344.23M, up 3.7% from the year before. The highest annual figure on record is $344.23M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $344.23M | +3.7% |
| FY2024 | Dec 31, 2024 | $332.07M | +51.1% |
| FY2023 | Dec 31, 2023 | $219.79M | +60.4% |
| FY2022 | Dec 31, 2022 | $137.04M | +45.7% |
| FY2021 | Dec 31, 2021 | $94.09M | +50.2% |
| FY2020 | Dec 31, 2020 | $62.65M | +20.8% |
| FY2019 | Dec 31, 2019 | $51.87M | +127.6% |
| FY2018 | Dec 31, 2018 | $22.79M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $102.89M | +23.9% |
| Q2 FY2026 | Jun 30, 2026 | $103.55M | +20.1% |
| Q1 FY2026 | Mar 31, 2026 | $83.68M | -4.9% |
| Q4 FY2025 | Dec 31, 2025 | $87.01M | +0.8% |
| Q3 FY2025 | Sep 30, 2025 | $83.04M | -3.2% |
| Q2 FY2025 | Jun 30, 2025 | $86.19M | -0.9% |
| Q1 FY2025 | Mar 31, 2025 | $87.99M | +20.6% |
| Q4 FY2024 | Dec 31, 2024 | $86.31M | +30.5% |
| Q3 FY2024 | Sep 30, 2024 | $85.78M | +39.5% |
| Q2 FY2024 | Jun 30, 2024 | $87.00M | +73.5% |
| Q1 FY2024 | Mar 31, 2024 | $72.97M | +73.6% |
| Q4 FY2023 | Dec 31, 2023 | $66.12M | +72.5% |
| Q3 FY2023 | Sep 30, 2023 | $61.49M | +66.1% |
| Q2 FY2023 | Jun 30, 2023 | $50.14M | +43.9% |
| Q1 FY2023 | Mar 31, 2023 | $42.04M | +56.6% |
| Q4 FY2022 | Dec 31, 2022 | $38.34M | +53.1% |
| Q3 FY2022 | Sep 30, 2022 | $37.01M | +57.7% |
| Q2 FY2022 | Jun 30, 2022 | $34.84M | +53.1% |
| Q1 FY2022 | Mar 31, 2022 | $26.85M | +17.7% |
| Q4 FY2021 | Dec 31, 2021 | $25.04M | +44.7% |
| Q3 FY2021 | Sep 30, 2021 | $23.48M | +54.3% |
| Q2 FY2021 | Jun 30, 2021 | $22.76M | +79.0% |
| Q1 FY2021 | Mar 31, 2021 | $22.81M | +31.0% |
| Q4 FY2020 | Dec 31, 2020 | $17.30M | -1.9% |
| Q3 FY2020 | Sep 30, 2020 | $15.22M | +3.0% |
| Q2 FY2020 | Jun 30, 2020 | $12.72M | +18.4% |
| Q1 FY2020 | Mar 31, 2020 | $17.42M | +99.8% |
| Q4 FY2019 | Dec 31, 2019 | $17.64M | +54.2% |
| Q3 FY2019 | Sep 30, 2019 | $14.77M | +298.0% |
| Q2 FY2019 | Jun 30, 2019 | $10.74M | +169.9% |
| Q1 FY2019 | Mar 31, 2019 | $8.72M | +138.2% |
| Q4 FY2018 | Dec 31, 2018 | $11.44M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.71M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.98M | – |
| Q1 FY2018 | Mar 31, 2018 | $3.66M | – |
See a number that looks wrong?